Bioresorbable scaffolds: Rationale, current status, challenges, and future

European Heart Journal

Volumn 35, Issue 12, 2014, Pages 765-776

  Iqbal, Javaid ^a   Onuma, Yoshinobu ^a   Ormiston, John ^b   Abizaid, Alexandre ^c   Waksman, Ron ^d   Serruys, Patrick ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^d WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Bioresorbable scaffolds; Coronary angioplasty; Drug eluting stents

Indexed keywords

ATHEROSCLEROSIS; BIORESORBABLE SCAFFOLD; CARDIOVASCULAR INFLAMMATION; CLINICAL TRIAL (TOPIC); DRUG ELUTING STENT; FOREIGN BODY; HUMAN; IN-STENT RESTENOSIS; MECHANOTRANSDUCTION; MEDICAL DEVICE COMPLICATION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SHEAR STRESS; STENT THROMBOSIS; THROMBOSIS; BIODEGRADABLE IMPLANT; BLOOD VESSEL PROSTHESIS; CORONARY STENOSIS; FORECASTING; GRAFT OCCLUSION, VASCULAR; PROSTHESIS; TISSUE SCAFFOLD; TRENDS;

METAL;

ABSORBABLE IMPLANTS; BLOOD VESSEL PROSTHESIS; CLINICAL TRIALS AS TOPIC; CORONARY STENOSIS; DRUG-ELUTING STENTS; FORECASTING; GRAFT OCCLUSION, VASCULAR; HUMANS; METALS; PROSTHESIS DESIGN; TISSUE SCAFFOLDS;

EID: 84896997274     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht542     Document Type: Review

References (80)

1. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978;1:263.
2. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61-68.
3. Sigwart U, Urban P, Golf S, Kaufmann U, Imbert C, Fischer A, Kappenberger L. Emer-gency stenting for acute occlusion after coronary balloon angioplasty. Circulation 1988;78:1121-1127.
4. Roubin GS, Cannon AD, Agrawal SK, Macander PJ, Dean LS, Baxley WA, Breland J. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation 1992;85:916-927.
5. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987; 316:701-706.
6. Serruys PW, Strauss BH, Beatt KJ, Bertrand ME, Puel J, Rickards AF, Meier B, Goy JJ, Vogt P, Kappenberger L. Angiographic follow-up after placement of aself-expanding coronary-artery stent. N Engl J Med 1991;324:13-17.
7. Iqbal J, Gunn J, Serruys PW. Coronary stents: historical development, current status and future directions. Br Med Bull 2013;106:193-211.
8. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-495.
9. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M. A randomized comparison of coronary-stent placement and balloonangioplastyinthe treatmentofcoronaryartery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
10. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, Kent KM, Griffin J, Leon MB. Patterns and mechanisms of in-stent restenosis. A serial intravas-cular ultrasound study. Circulation 1996;94:1247-1254.
11. Gordon PC, Gibson CM, Cohen DJ, Carrozza JP, Kuntz RE, Baim DS. Mechanisms of restenosis and redilation within coronary stents-quantitative angiographic assessment. J Am Coll Cardiol 1993;21:1166-1174.
12. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
13. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
14. Mc Fadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-1521.
15. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-1019.
16. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362: 1663-1674.
17. Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S, Juni P. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011;378:1940-1948.
18. Iqbal J, Sumaya W, Tatman V, Parviz Y, Morton AC, Grech ED, Campbell S, Storey RF, Gunn J. Incidence and predictors of stent thrombosis: a single-centre study of 5, 833 consecutive patients undergoing coronary artery stenting. Euro Intervention 2013;9: 62-69.
19. Waksman R. Biodegradable stents: they do their job and disappear. J Invasive Cardiol 2006;18:70-74.
20. Wykrzykowska JJ, Onuma Y, Serruys PW. Vascular restoration therapy: the fourth revolution in interventional cardiology and the ultimate 'rosy' prophecy. Euro Inter-vention 2009;5(Suppl F):F7-F8.
21. Gomez-Lara J, Garcia-Garcia HM, Onuma Y, Garg S, Regar E, De Bruyne B, Windecker S, Mc Clean D, Thuesen L, Dudek D, Koolen J, Whitbourn R, Smits PC, Chevalier B, Dorange C, Veldhof S, Morel MA, de Vries T, Ormiston JA, Serruys PW. A comparison of the conformability of everolimus-eluting bioresorb-able vascular scaffolds to metal platform coronary stents. JACC Cardiovasc Interv 2010;3:1190-1198.
22. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient biore-sorbable scaffolds: changeinparadigmofcoronary revascularizationinthe upcoming decade? Eur Heart J 2012;33:16-25b.
23. Okamura T, Serruys PW, Regar E. Cardiovascular flashlight. The fate of bioresorb-able struts located at a side branch ostium: serial three-dimensional optical coherence tomography assessment. Eur Heart J 2010;31:2179.
24. Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation 2011;123: 779-797.
25. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, Komori H, Tsuji T, Motohara S, Uehata H. Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans. Circulation 2000;102:399-404.
26. Moravej M, Mantovani D. Biodegradable metals for cardiovascular stent application: interests and new opportunities. Int J Mol Sci 2011;12:4250-4270.
27. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M, Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910.
28. Bruining N, Tanimoto S, Otsuka M, Weustink A, Ligthart J, de Winter S, van Mieghem C, Nieman K, de Feyter PJ, van Domburg RT, Serruys PW. Quantitative multi-modality imaging analysis of a bioabsorbable poly-L-lactic acid stent design in the acute phase: a comparison between 2-and 3D-QCA, QCU and QMSCT-CA. Euro Intervention 2008;4:285-291.
29. Garcia-Garcia HM, Gonzalo N, Pawar R, Kukreja N, Dudek D, Thuesen L, Ormiston JA, Regar E, Serruys PW. Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strainvalues and tissuecompositionusing intravascularultrasoundradiofrequency data analysis. A substudy of the ABSORB clinical trial. Euro Intervention 2009;4: 443-448.
30. Dudek D, Onuma Y, Ormiston JA, Thuesen L, Miquel-Hebert K, Serruys PW. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. Euro In-tervention 2012;7:1060-1061.
31. Onuma Y, Nieman K, Webster M, Thuesen L, Dudek D, Ormiston JA, Serruys PW. Five-year clinical outcomes and non-invasive angiographic imaging results with functional assessment after bioresorbable everolimus-eluting scaffold implantation in patients with de novo coronary artery disease. J Am Coll Cardiol 2012;60(Suppl 17).
32. Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, vanGeuns RJ, deBruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, Mc Clean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Ormiston JA. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. Euro Intervention 2013; pii: 20131017e:[Epub ahead of print].
33. Gomez-Lara J, Brugaletta S, Farooq V, Onuma Y, Diletti R, Windecker S, Thuesen L, Mc Clean D, Koolen J, Whitbourn R, Dudek D, Smits PC, Chevalier B, Regar E, Veldhof S, Rapoza R, Ormiston JA, Garcia-Garcia HM, Serruys PW. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography. JACC Cardiovasc Interv 2011;4:1271-1280.
34. de Ribamar Costa J, Verheye S, Webster M, Stewart J, Abizaid A, Costa R, Staico R, Chamie D, Bhat V, Morrison L, Toyloy S, Ormiston J, Middehein ZNA. Six-month intravascular ultrasound analysis of the DESOLVE FIM trial with a novel PLLA-based fully biodegradable drug-eluting scaffold. J Am Coll Cardiol 2013;61(Suppl 10):E1646.
35. Abizaid A. First report on the Pivotal DESolve Nx Trial: 6-month clinical and multi-modality imaging results. In: Euro PCR, Paris, France 2013.
36. Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR, Erne P, Haude M, Heublein B, Horrigan M, Ilsley C, Bose D, Koolen J, Luscher TF, Weissman N, Waksman R, Investigators P-A. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007;369:1869-1875.
37. Waksman R, Erbel R, Di Mario C, Bartunek J, deBruyne B, Eberli FR, Erne P, Haude M, Horrigan M, Ilsley C, Bose D, Bonnier H, Koolen J, Luscher TF, Weissman NJ, Investigators P-A. Early-and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantationin human coronary arteries. JACC Cardiovasc Interv 2009;2:312-320.
38. Haude M, Erbel R, Erne P, Verheye S, Degen H, Bose D, Vermeersch P, Wijnbergen I, Weissman N, Prati F, Waksman R, Koolen J. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet 2013;381:836-844.
39. Haude M. Two-year clinical data and multi-modality imaging results up to 1-year follow-up of the BIOSOLVE-I study with the paclitaxel-eluting bioabsorbable magnesium scaffold (DREAMS). In: Euro PCR, Paris, France, 2013.
40. Grube E. Bioabsorbable stent. The Boston Scientific and REVA technology. In: Euro PCR, Barcelona, Spain, 2009.
41. Costa RA. REVA Re Zolve clinical program update. In: Transcatheter Cardiovascular Therapeutics, Miami Beach, FL, 2012.
42. Lafont A, Durand E. A. R. T. concept of a bioresorbable stent without drug elution. Euro Intervention 2009;5(Suppl F):F83-F87.
43. Durand E, Lemitre M, Couty L, Sharkawi T, Brasselet C, Vert M, Lafont A. Adjusting a polymerformulation foran optimal bioresorbable stent: a 6-month follow-up study. Euro Intervention 2012;8:242-249.
44. Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, Kolodgie FD, Finn AV, Virmani R. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011;57: 1314-1322.
45. Granada J. The Amaranth Stent: Design and Future Directions. In: TCT, Miami, FL, USA, 2012.
46. Iqbal J. Anon drug-eluting PLLA scaffold with high flexibility and strength. In: Euro PCR, Paris, France, 2013.
47. Jabara R, Chronos N, Robinson K. Novel bioabsorbable salicylate-based polymer as a drug-eluting stent coating. Catheter Cardiovasc Interv 2008;72:186-194.
48. Jabara R, Pendyala L, Geva S, Chen J, Chronos N, Robinson K. Novel fully bioabsorb-able salicylate-based sirolimus-eluting stent. Euro Intervention 2009;5(Suppl F): F58-F64.
49. Jabara R. Assessment of a novel fully bio-absorbable salicylate-based sirolimus-eluting stent. In: Euro PCR, Barcelona, Spain, 2009.
50. Jabara R. Bio-mechanical properties and ABC of bioresorption of adipic acid. In: PCR focus group on bioresorbable vascular scaffolds, Rotterdam, The Netherlands, 2012.
51. Waksman R, Pakala R, Baffour R, Seabron R, Hellinga D, Tio FO. Short-term effects of biocorrodible iron stents in porcine coronary arteries. J Interv Cardiol 2008;21: 15-20.
52. Wu C, Hu X, Qiu H, Ruan Y, Tang Y, Wu A, Tian Y, Peng P, Chu Y, Xu X, Wang Q, Xu L, Xu B, Zhang D, Gao R-L. TCT-571 A preliminary study of biodegradable iron stent in mini-swine coronary artery. J Am Coll Cardiol 2012;60(Suppl 17): B166.
53. Wu Y, Shen L, Wang Q, Ge L, Xie J, Hu X, Sun A, Qian J, Ge J. Comparison of acute recoil between bioabsorbable poly-L-lactic acid XINSORB stent and metallic stent in porcine model. J Biomed Biotechnol 2012;2012:413956.
54. Grogan JA, Leen SB, Mc Hugh PE. Comparing coronary stent material performance on a common geometric platform through simulated bench testing. J Mech Behav Biomed Mater 2012;12:129-138.
55. Tanimoto S, Serruys PW, Thuesen L, Dudek D, de Bruyne B, Chevalier B, Ormiston JA. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv 2007;70:515-523.
56. Onuma Y, Serruys PW, Gomez J, de Bruyne B, Dudek D, Thuesen L, Smits P, Chevalier B, Mc Clean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia H, Ormiston JA, ABSORB Cohort Aand Binvestigators. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1. 0 and 1. 1) and the metallic everolimus-eluting stent. Catheter Cardiovasc Interv 2011;78:3-12.
57. Onuma Y, Serruys PW, Perkins LE, Okamura T, Gonzalo N, Garcia-Garcia HM, Regar E, Kamberi M, Powers JC, Rapoza R, van Beusekom H, van der Giessen W, Virmani R. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 2010;122: 2288-2300.
58. Waksman R, Pakala R, Kuchulakanti PK, Baffour R, Hellinga D, Seabron R, Tio FO, Wittchow E, Hartwig S, Harder C, Rohde R, Heublein B, Andreae A, Waldmann KH, Haverich A. Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheter Cardiovasc Interv 2006;68:607-617; discussion 618-619.
59. Lu P, Cao L, Liu Y, Xu X, Wu X. Evaluation of magnesium ions release, biocorrosion, and hemocompatibility of MAO/PLLA-modified magnesium alloy WE42. J Biomed Mater Res B Appl Biomater 2011;96:101-109.
60. Wentzel JJ, Whelan DM, van der Giessen WJ, van Beusekom HM, Andhyiswara I, Serruys PW, Slager CJ, Krams R. Coronary stent implantation changes 3-D vessel geometry and 3-D shear stress distribution. J Biomech 2000;33:1287-1295.
61. Gyongyosi M, Yang P, Khorsand A, Glogar D. Longitudinal straightening effect of stents is an additional predictor for major adverse cardiac events. Austrian Wiktor Stent Study Group and European Paragon Stent Investigators. J Am Coll Cardiol 2000;35:1580-1589.
62. Gomez-Lara J, Brugaletta S, Farooq V, van Geuns RJ, De Bruyne B, Windecker S, Mc Clean D, Thuesen L, Dudek D, Koolen J, Whitbourn R, Smits PC, Chevalier B, Morel MA, Dorange C, Veldhof S, Rapoza R, Garcia-Garcia HM, Ormiston JA, Serruys PW. Angiographic geometric changes of the lumen arterial wall after bioresorbable vascular scaffolds and metallic platform stents at 1-year follow-up. JACC Cardiovasc Interv 2011;4:789-799.
63. Brugaletta S, Heo JH, Garcia-Garcia HM, Farooq V, van Geuns RJ, de Bruyne B, Dudek D, Smits PC, Koolen J, Mc Clean D, Dorange C, Veldhof S, Rapoza R, Onuma Y, Bruining N, Ormiston JA, Serruys PW. Endothelial-dependent vasomo-tion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold systemisrelatedtoplaque compositionatthe timeofbioresorption of the polymer: indirect finding of vascular reparative therapy? Eur Heart J 2012;33: 1325-1333.
64. Brugaletta S, Gogas BD, Garcia-Garcia HM, Farooq V, Girasis C, Heo JH, van Geuns RJ, de Bruyne B, Dudek D, Koolen J, Smits P, Veldhof S, Rapoza R, Onuma Y, Ormiston J, Serruys PW. Vascular compliance changes of the coronary vessel wall after bioresorbable vascular scaffold implantation in the treated and adjacent segments. Circ J 2012;76:1616-1623.
65. Ghimire G, Spiro J, Kharbanda R, Roughton M, Barlis P, Mason M, Ilsley C, Di Mario C, Erbel R, Waksman R, Dalby M. Initial evidence for the return of coronary vasoreac-tivity following the absorption of bioabsorbable magnesium alloy coronary stents. Euro Intervention 2009;4:481-484.
66. Di Mario C, Borgia F. Assimilating the current clinical data of fully bioabsorbable stents. Euro Intervention 2009;5:F103-F108.
67. Yamaji K, Kimura T, Morimoto T, Nakagawa Y, Inoue K, Kuramitsu S, Soga Y, Arita T, Shirai S, Ando K, Kondo K, Sakai K, Iwabuchi M, Yokoi H, Nosaka H, Nobuyoshi M. Very long-term (15 to 23 years) outcomes of successful balloon angioplasty compared with bare metal coronary stenting. J Am Heart Assoc 2012;1:e004085.
68. Wykrzykowska JJ, Diletti R, Gutierrez-Chico JL, van Geuns RJ, van der Giessen WJ, Ramcharitar S, Duckers HE, Schultz C, de Feyter P, van der Ent M, Regar E, de Jaegere P, Garcia-Garcia HM, Pawar R, Gonzalo N, Ligthart J, de Schepper J, van den Berg N, Milewski K, Granada JF, Serruys PW. Plaque sealing and passivation with a mechanical self-expanding low outward force nitinol vShield device for the treatment ofIVUS and OCT-derived thin capfibroatheromas (TCFAs) in native coronary arteries: report of the pilot study vShield Evaluated at Cardiac hospital in Rotterdam for Investigation and Treatment of TCFA (SECRITT). Euro Intervention 2012; 8:945-954.
69. Brugaletta S, Radu MD, Garcia-Garcia HM, Heo JH, Farooq V, Girasis C, van Geuns RJ, Thuesen L, Mc Clean D, Chevalier B, Windecker S, Koolen J, Rapoza R, Miquel-Hebert K, Ormiston J, Serruys PW. Circumferential evaluation of the neoin-tima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffoldcap theplaque? Atherosclerosis 2012;221:106-112.
70. Ormiston JA, Serruys PW, Onuma Y, van Geuns RJ, de Bruyne B, Dudek D, Thuesen L, Smits PC, Chevalier B, Mc Clean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Rapoza R, Garcia-Garcia HM. First serial assessment at6 months and2yearsofthe second gen-erationofabsorb everolimus-eluting bioresorbable vascular scaffold:amulti-imaging modality study. Circ Cardiovasc Interv 2012;5:620-632.
71. Iqbal J, Serruys PW, Taggart DP. Optimal revascularization for complex coronary artery disease. Nat Rev Cardiol 2013;10:635-647.
72. Fernandez D, Brugaletta S, Martin-Yuste V, Regueiro A, de Mingo A, Santos A, Masotti M, Sabate M. First experience of a bioresorbable vascular scaffold implantation in left main stenosis. Int J Cardiol 2013;168:1566-1568.
73. Diletti R, Farooq V, Girasis C, Bourantas C, Onuma Y, Heo JH, Gogas BD, van Geuns RJ, Regar E, de Bruyne B, Dudek D, Thuesen L, Chevalier B, Mc Clean D, Windecker S, Whitbourn RJ, Smits P, Koolen J, Meredith I, Li X, Miquel-Hebert K, Veldhof S, Garcia-Garcia HM, Ormiston JA, Serruys PW. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffoldsinsmall vessels. Late lumen enlargement: does bior-esorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart 2013;99:98-105.
74. Ormiston JA, De Vroey F, Serruys PW, Webster MW. Bioresorbable polymeric vascular scaffolds: a cautionary tale. Circ Cardiovasc Interv 2011;4:535-538.
75. Muramatsu T, Onuma Y, Garcia-Garcia HM, Farooq V, Bourantas CV, Morel MA, Li X, Veldhof S, Bartorelli A, Whitbourn R, Abizaid A, Serruys PW, Investigators S-E. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT First and II trials. JACC Cardiovasc Interv 2013;6:247-257.
76. Kajiya T, Liang M, Sharma RK, Lee CH, Chan MY, Tay E, Chan KH, Tan HC, Low AF. Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). Euro Intervention 2013;9: 501-504.
77. Onuma Y, Garg S, Okamura T, Ligthart J, van Geuns RJ, de Feyter PJ, Serruys PW, Tamai H. Ten-year follow-up of the IGAKI-TAMAI stent. A posthumous tribute to the scientific work of Dr. Hideo Tamai. Euro Intervention 2009;5(Suppl F): F109-F111.
78. Nishio S, Kosuga K, Igaki K, Okada M, Kyo E, Tsuji T, Takeuchi E, Inuzuka Y, Takeda S, Hata T, Takeuchi Y, Kawada Y, Harita T, Seki J, Akamatsu S, Hasegawa S, Bruining N, Brugaletta S, de Winter S, Muramatsu T, Onuma Y, Serruys PW, Ikeguchi S. Long-term (. 10 Years) clinical outcomes of first-in-human biodegradable poly-L-lactic acid coronary stents: Igaki-Tamai stents. Circulation 2012;125:2343-2353.
79. Serruys P. Preliminary data from ABSORB EXTEND: a report of the 12-month clinical outcomes from the first 450 patients enrolled. In: Euro PCR, Paris, France, 2013.
80. Diletti R, Serruys PW, Farooq V, Sudhir K, Dorange C, Miquel-Hebert K, Veldhof S, Rapoza R, Onuma Y, Garcia-Garcia HM, Chevalier B. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease causedbydenovo native coronary artery lesions: rationale and study design. Am Heart J 2012;164:654-663.